Virax Biolabs (NASDAQ:VRAX) Soars 183% After Fosun Deal
Virax Biolabs Group shares jumped more than 100% during Thursday’s U.S. session after the diagnostics company said its UK subsidiary reached an exclusive multi-country supply deal with Fosun Diagnostics for its ImmuneSelect research-use immune-profiling line. The Nasdaq stock was trading at $9.00 as of 11:52 a.m. EDT, up $5.82 on the day, with about 57.8 million shares changing hands.
